161 related articles for article (PubMed ID: 22289993)
21. ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.
Rossi D; Gaidano G
Haematologica; 2012 Jan; 97(1):5-8. PubMed ID: 22210328
[No Abstract] [Full Text] [Related]
22. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
23. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
25. A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.
Gardiner A; Parker H; Glide S; Mould S; Robinson H; Tracy I; Stankovic T; Oscier D; Strefford J
Leuk Res; 2012 Mar; 36(3):307-10. PubMed ID: 21955805
[TBL] [Abstract][Full Text] [Related]
26. No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia.
Mikeska T; Carney DA; Seymour JF; Dobrovic A
Leuk Lymphoma; 2012 Jul; 53(7):1420-2. PubMed ID: 22204453
[No Abstract] [Full Text] [Related]
27. Chronic lymphocytic leukemia: a niche for flavopiridol?
Brown JR
Clin Cancer Res; 2005 Jun; 11(11):3971-3. PubMed ID: 15930331
[No Abstract] [Full Text] [Related]
28. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
29. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Pepper C; Thomas A; Hoy T; Fegan C; Bentley P
Br J Haematol; 2001 Jul; 114(1):70-7. PubMed ID: 11472347
[TBL] [Abstract][Full Text] [Related]
30. Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation.
Dyer MJ; Majid A; Walewska R; Gesk S; Harder L; Siebert R; Morgan B
Leuk Res; 2011 May; 35(5):e55-7. PubMed ID: 21185599
[No Abstract] [Full Text] [Related]
31. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Stephens DM; Ruppert AS; Jones JA; Woyach J; Maddocks K; Jaglowski SM; Andritsos LA; Flynn JM; Grever MR; Lozanski G; Johnson AJ; Muthusamy N; Heerema NA; Byrd JC
Leukemia; 2014 Jun; 28(6):1365-8. PubMed ID: 24451411
[No Abstract] [Full Text] [Related]
32. Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.
Pierceall WE; Warner SL; Lena RJ; Doykan C; Blake N; Elashoff M; Hoff DV; Bearss DJ; Cardone MH; Andritsos L; Byrd JC; Lanasa MC; Grever MR; Johnson AJ
Leukemia; 2014 Nov; 28(11):2251-4. PubMed ID: 24990615
[No Abstract] [Full Text] [Related]
33. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.
Ripollés L; Ortega M; Ortuño F; González A; Losada J; Ojanguren J; Soler JA; Bergua J; Coll MD; Caballín MR
Cancer Genet Cytogenet; 2006 Nov; 171(1):57-64. PubMed ID: 17074592
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
35. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B; Lin TT; Ahmed G; Weston V; Jones RE; Fegan C; Oscier DG; Stankovic T; Pepper C; Baird DM
Leukemia; 2012 Apr; 26(4):826-30. PubMed ID: 21986843
[No Abstract] [Full Text] [Related]
36. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
38. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
40. Flavopiridol: where do we stand in chronic lymphocytic leukemia?
Lin TS; Porcu P
Leukemia; 2004 Feb; 18(2):243-6. PubMed ID: 14671637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]